Stress echocardiography: safety and tolerability by Nada Fennich et al.
CARDIOVASCULAR 
ULTRASOUND
Fennich et al. Cardiovascular Ultrasound 2013, 11:30
http://www.cardiovascularultrasound.com/content/11/1/30TECHNICAL NOTES Open AccessStress echocardiography: safety and tolerability
Nada Fennich1†, Fedoua Ellouali1,3*, Salima Abdelali2, Assad Chaara2, Allal Berrada2, Imane Elhajjaji1,
Rhizlane Cherradi2, Saadia Abir2, Nawal Doghmi1† and Mohammed Cherti1Abstract
Background: Stress echocardiography is a valuable tool for the noninvasive diagnosis of ischemic heart disease.
Despite its widely use in the clinical practice, safety and side effects profile have never been evaluated in
Moroccans.
The aim: To assess the safety and tolerability of the two stress echo modalities in Moroccans.
Methods: The study was made by 311 patients with known or suspected coronary artery disease, 203 underwent
exercise echocardiography and 108 underwent dobutamine echocardiography, major and minor rhythmic
complications and side effects were recorded for the two groups.
Results: We registered 3 (2, 8%) major rhythmic events in the dobutamine group (2 sustained supraventricular
tachycardia and 1 sustained ventricular tachycardia), there was no major rhythmic events in the exercise group.
Minor rhythmic events were frequent (43, 5% in the dobutamine group and 19, 2% in the exercise group with a
p = 0, 0001). Severe hypotension occurs in 4 (3, 7%) patients during a dobutamine stress, there was no significant
drop in the blood pressure during exercise stress procedures. Non cardiac side effects were more common among
patients who underwent a dobutamine stress echo (13, 9% vs. 3, 4% with p = 0,001).
Conclusion: Exercise is safer than dobutamine stress echocardiography, complications and adverse effects with the
use of dobutamine are usually minor and self-limiting.
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Stress echocardiography is an established clinical testing
method for the detection of coronary artery disease. The
exam end point is the development of a left ventricular
regional myocardial dysfunction traducing a transient
imbalance between oxygen demand and supply in ische-
mic conditions. The myocardial wall motion abnormality
is an earlier and a more sensitive marker for myocardial
ischemia than electrocardiographic changes or chest
pain alone.
Exercise used for the first time in combination with a
two dimensional echocardiography in 1979, is a simple
and physiologic tool. Exercise stress echocardiography
should be the first choice in patients with suspected* Correspondence: f.ellouali@hotmail.com
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reproduction in any medium, provided the orcoronary artery disease. Pharmacological stressors have
been developed to evaluate patients unable to exercise
with neurological, orthopedic, peripheral vascular or re-
spiratory problems, dobutamine is the most used.
Safety and tolerability of the different stress modalities
have been investigated in numerous studies. This is the
first study conducted in Moroccan labs.Methods
Population study
We retrospectively studied 311 patients with known or
suspected coronary artery disease, referred to our depart-
ment for a myocardial ischemia assessment between 2006
and 2012. 203 underwent exercise stress echocardiography
(160 males, mean age 59.2+/−8.6 years) and 108 had
dobutamine stress echocardiography (48 males, mean age
62.9+/−11.3 years). Clinical characteristics including a his-
tory of diabetes, hypertension, hypercholesterolemia,
cigarette smoking, ischemic disease related medications,
prior myocardial infarction, prior percutaneous coronaryl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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recorded for all patients.
Stress protocol
Exercise stress echo was conducted using a semi-supine
bicycle ergometer with 25 W incremental loading every
2 minutes. At the end of each stage, the heart rate, the
blood pressure and a 12-lead ECG were recorded. Echo-
cardiographic images were acquired with the patient on
the bicycle at rest, at peak exercise and at recovery
period.
Pharmacological stress echo was performed using
dobutamine. Dobutamine was administered intraven-
ously with an infusion pump, beginning at a dose of 5 to
10 μg/kg per minute and increased by 10 μg/kg every
3 minutes up to a maximum of 40 μg/kg per minute. At-
ropine was added at doses of 0.25 mg each minute to a
maximum of 2 mg when starting the dobutamine dose
of 20 μg/kg/min if heart rate was <100 beats/min. The
blood pressure, the heart rate and clinical symptoms
were monitored; a 12-lead electrocardiogram was
obtained at baseline, at the start of the dobutamine infu-
sion and at the end of each 3-min interval. Echocardio-
graphic images were acquired at rest, at small doses, at
peak dose and at recovery period.
Echocardiographic analysis
Images in standard views were acquired and displayed side
by side in a quad-screen format. All images were recorded
on videotape and digitized in continuous-loop format. The
left ventricle was divided into 17 segments according to
the recommendations of the American Society of Echocar-
diography [1]. A 4-point score was assigned to each seg-
ment as follows: 1 = normal, 2 = hypokinesia, 3 = akinesia,
and 4 = dyskinesia. A wall motion score index was derived
by dividing the sum of individual segment scores by the
number of interpretable segments. A normal stress re-
sponse is defined by a uniform increase in wall motion and
systolic wall thickening, with a reduction in end-systolic
cavity area. Ischemic response was defined as the develop-
ment of new or the worsening of pre-existing wall motion
abnormalities in 2 contiguous segments. The “bi-
phasic” response (low-dose improvement followed by
high-dose deterioration) was also regarded as criterion
for ischemia [2], whereas rest akinesia becoming dys-
kinesia was not. Images analysis was made by the same
experimented operator (N.D).
Tests interruption
Stress echo was stopped when 85% of age-predicted tar-
get heart rate was reached, if the patient developed se-
vere chest pain, ST segment elevation > 0.1 mV at 80 ms
from the J point, new segmental wall motion abnormal-
ities or significant adverse effects.Adverse events definitions
Major rhythmic events are defined as a life threatens
rhythmic complications (cardiac asystole, advanced
atrioventricular block, ventricular fibrillation or ven-
tricular sustained tachycardia) or complications that re-
quire hospital admission (supraventricular tachycardia).
Minor rhythmic events are defined as the development
of uniform or multiform premature ventricular beats,
ventricular bigeminy or couplets and nonsustained ven-
tricular tachycardia.
Severe hypotension was defined by an arterial pressure
drop ≥ 40 mmHg with symptoms.
Minor side effects were defined as the development of
headache, nausea and muscular pain.
Statistical analysis
Continuous variables are expressed as means ± standard
deviations and categorical variables are expressed as per-
centages. To compare between the dobutamine echocar-
diography group and the exercise echocardiography
group, the continuous variables were analyzed using Stu-
dent’s t-test and the categorical variables were analyzed
using the Chi-square test. A p < 0.05 was considered sta-
tistically significant.
The statistical analysis was performed using Statistical
Package for the Social Sciences (SPSS) version 18.0
(SPSS Inc., Chicago, IL, USA).
Results
A total of 311 patients were enrolled, the average age
was 61 years old, and 67% were male. The study popula-
tion comprised two groups: The exercise group which
included 203 patients and the dobutamine group which
included 108 patients. Demographic and clinical charac-
teristics of the two groups are represented in Table 1.
Stress tests were maximal in 81.37% for exercise echo
and 88.34% for dobutamine echo (p =NS); the percentage
of age predicted heart rate reached by exercise was 90.51%
and 92.89% for dobutamine. The maximal heart rate was
145.42+/−17.29 beat per minute for exercise and
146.00+/−18.17 beat per minute for dobutamine with a
non-significant difference. Exercise was associated with higher
maximal systolic blood pressure (190.25+/−29.03 mmHg
versus 170.73+/−35.67 mmHg, p = 0.0001) and higher
maximal diastolic blood pressure (91.37+/−16.18 mmHg
versus 80.50+/−16.58 mmHg, p = 0.0001).
Echocardiographic positive responses were more fre-
quently observed with the dobutamine echocardiog-
raphy. Results of the two stress tests are represented in
the Table 2.
In the presented study, no death, cardiac rupture or
myocardial infarction were registered.
Dobutamine infusion showed higher incidence of
rhythmic complications, major events were observed in
Figure 1 Electrocardiogram showing a run of ventricular
tachycardia.






Age (years) 59.2 62.9 0.001
Masculine gender (%) 78.9 44.4 0.0001
Diabetes (%) 27.1 44.4 0.002
Hypertension (%) 38.4 59.3 0.001
Hypercholesterolemia (%) 35 35.2 NS
Smoking (%) 47.8 26.9 0.0001
Optimal medical treatment (%) 53.4 41.7 NS
Prior myocardial infarction (%) 21.07 11.11 0.029
Prior coronary angioplasty (%) 53.7 20.4 0.0001
Prior coronary artery bypass
grafting (%)
1 6.5 0.01
Left ventricular dysfunction (%) 13.79 11.11 NS
NS Non-significant.
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and 1 sustained ventricular tachycardia (Figure 1)).
Supra ventricular tachycardia was registered in 2 pa-
tients (a 70 year-old women and a 55 year-old man)
with no history of arrhythmia, with a normal left ven-
tricular function and no induced myocardial ischemia.
Ventricular tachycardia occurs in a 65 year-old diabetic
patient with no history of myocardial infarction, addressed
for silent myocardial ischemia screening, the left ventricu-
lar function was normal, the dobutamine stress echo was
negative. In the exercise group, there was no major rhyth-
mic event.
Minor rhythmic complications were registered in
19.2% in the exercise group and in 43.5% in the
dobutamine group. In the exercise group, minor events
included isolated supra ventricular premature beats in 3
patients (1.47%), isolated ventricular premature beats in
31 (15.27%), bigeminy or couplets in 4 (1.97%) and non-
sustained ventricular tachycardia in 1 (0.49%). In the
dobutamine group isolated supra ventricular premature
beats occurs in 5 patients (4.62%), isolated ventricular
premature beats in 34 (31.48%), bigeminy or couplets in
7 (6.48%) and non-sustained ventricular tachycardia in 1Table 2 Results of the stress tests in the study population
Results Stress modality P
Exercise Dobutamine
Echocardiographic positivity (%) 13.2 23.1 0.003
Major rhythmic events (%) 0 2.8 NS
Minor rhythmic events (%) 19.2 43.5 0.0001
Severe hypotension (%) 0 3.7 NS
Minor side effects (%) 3.4 13.9 0.001
NS Non significant.patient (0.92%). All minor rhythmic complications were
well tolerated.
No blood pressure decrease was seen during exercise
but dobutamine infusion provoked severe systolic pres-
sure fall in 4 (3.7%) subjects. 1 developed convulsions
while 3 had only vertigo. Myocardial ischemia was
present in 2 patients.
Non cardiac side effects appeared with both physical
exercise and dobutamine infusion with higher incidence
with the use of dobutamine as stressor.
In univariate analysis, dobutamine infusion provoked
more minor rhythmic complications and non-cardiac
side effects than the physical exercise.
Dobutamine infusion was associated to atropine admin-
istration in 78.5% of dobutamine tests, the mean dose was
0.66+/−0.55 mg. Adverse events were comparable in the
group of patients with and without atropine co adminis-
tration: major rhythmic complications occur in 3.6% ver-
sus 0 (p =NS), minor rhythmic complications were
registered in 41.7% versus 52.2% (p =NS), hypotension
was observed in 4.8% versus 0 (p =NS) and non-cardiac
side effects appeared in 15.47% versus 8.7% (p =NS).
The use of atropine in dobutamine tests was not asso-
ciated to higher incidence of adverse events.
Discussion
Both stress modalities are safe. The occurrence of life
threatening complications is rare. Data from the Inter-
national Stress Echo Complication Registry reports a
rate of 1 of 6574 patients undergoing exercise stress
Echo and 1 of 557 patients undergoing dobutamine
stress Echo [3].
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lar fibrillation or high conduction disturbances were ob-
served. Several studies reported an incidence of 0.002%,
0.02%, 0.04% and 0.23% respectively with the use of
dobutamine as stressor [4]. We registered 1 case of
sustained ventricular tachycardia in the dobutamine
group, the reported incidence is 0.15% [4]. The clinical
significance of Dobutamine stress echo induced ven-
tricular tachycardia has not been clarified. Previous stud-
ies [5-7] failed to establish a relationship between this
ventricular rhythm disturbance and inductile myocardial
ischemia. Elhendy et al. [8], in a series of 286 patients
who underwent dobutamine stress echo and subsequent
coronary angiography, reported that tachyarrhythmia
during dobutamine stress were not predicted by the
presence or the extent of coronary artery disease on
angiography nor by the induction of ischemia during the
stress echo. The arrhythmia may be attributed to beta
1-receptor stimulation, to dobutamine induced reduction
in ventricular refractory period [9] or to a dobutamine-
induced reduction in plasma potassium [10].
In the presented study, supraventricular tachycardia
occurred in 2 (1.8%) dobutamine tests. Similar results
were reported by Secknus et al. (1.7%), Pezzano et al.
(1.6%) and Tsutsui et al. (1.6%) [11-13]. Supraventric-
ular arrhythmias seem to be more frequent in older
patients [14].
Minor rhythmic complications were observed in both
stress modalities with a statistically higher incidence in
the dobutamine group. Minor events included prema-
ture ventricular beats and nonsustained ventricular
tachycardia NSVT, the reported incidence is 33.7% and
2.1% respectively [12]. In a previous study, the prognos-
tic significance of NSVT during dobutamine stress echo
was explored, there was no difference in survival over
the 3 years follow-up between the NSTV and the no
NSTV groups in patients without inducible ischemia and
with an ejection fraction > 0.45 [15].
Severe hypotension occurred in 3.7% of dobutamine
tests, the reported incidence is 20% [4]. Although
hypotensive response during exercise has strongly been
associated to myocardial ischemia and poor cardiac
prognostic, hypotension during dobutamine infusion
cannot be consider as a specific indicator of cardiac
anomalies [16]. The mechanism of hypotensive response
during dobutamine infusion remains unclear, vigorous
myocardial contraction around a small chamber may
trigger sympathoinhibition and increased parasympa-
thetic discharge, leading to a systemic hypotension [17].
The prognostic significance has been widely discussed,
most studies did not reported a significant association
with cardiac complications occurrence, while Dunkelgrun
et al. in a retrospective study of 3381 patients showed that
severe hypotension during dobutamine infusion is anindependent predictor of cardiac death and non-fatal
myocardial infarction [18].
Atropine co administration in dobutamine stress echo-
cardiography is a safe and effective strategy in patients
who had inadequate chronotropic response. Atropine
adjunction was first reported by Mc Neill et al. [19], if
85% of maximal predicted heart rate was not achieved at
the end of the last stage, atropine was administered in
doses of 0.25 mg each minute to a maximum of 1.0 mg
while maintaining a continuous infusion of dobutamine.
Recently, new protocols have been developed including
the early injection of atropine at the dose of 20 μ/Kg/min
when the heart rate is < 100 beats per minute. The early
injection of atropine during dobutamine stress echo has
been demonstrated to reduce the duration and dose of
dobutamine infusion, to reduce dobutamine related ad-
verse events, while at the same time preserving a similar
diagnostic accuracy.
In our study, we used the early atropine protocol. At-
ropine administration was not associated to higher inci-
dence of adverse events [20].
Stress modalities are safe but not equally safe, exercise
tests are safer. The most common adverse events are the
rhythmic disturbances and are usually minor and well
tolerated.
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